Revance's Long-Acting RT002 Will Have Slow-Moving Impact On Allergan

Phase III data show statistically significant wrinkle-reducing results for up to six months across two trials for Revance's neuromodulator RT002. With a safety study ongoing, the Botox competitor isn't likely to hit the market until 2020, but it's yet another piece of bad news for Allergan.

Revance Therapeutics Inc. is riding high after announcing its RT002 (daxibotulinumtoxinA) provided long-lasting wrinkle-reducing effects for up to six months in two Phase III trials, potentially besting Botox (onabotulinumtoxinA), but Allergan PLC threw doubt on such claims and stood by the longevity and market share of its blockbuster product.

The biotech's stock rose 33.7% to close at $34

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

06 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.